

## Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

F. J. Afonso · U. Anido · O. Fernández-Calvo ·  
S. Vázquez-Estévez · L. León · M. Lázaro ·  
M. Ramos · L. Antón-Aparicio

Published online: 4 April 2013  
© Federación de Sociedades Españolas de Oncología (FESEO) 2013

**Erratum to: Clin Transl Oncol**  
DOI 10.1007/s12094-012-0985-x

Unfortunately, the original publication contains two errors.

1. Table 2 has been published incorrectly, the correct version is given below:
2. Reference 9 is not correct, the reference should read as follows:

---

The online version of the original article can be found under doi:10.1007/s12094-012-0985-x.

---

F. J. Afonso  
Complejo Hospitalario Arquitecto Marcide, Ferrol, Spain

U. Anido · L. León  
Complejo Hospitalario Universitario de Santiago,  
Santiago de Compostela, Spain

O. Fernández-Calvo  
Complejo Hospitalario Universitario de Ourense,  
Ourense, Spain

S. Vázquez-Estévez  
Hospital Universitario Lucus Augustí, Lugo, Spain

M. Lázaro  
Complejo Hospitalario Universitario, Vigo, Spain

M. Ramos  
Centro Oncológico de Galica, A Coruña, Spain

L. Antón-Aparicio (✉)  
Medical Oncology Service, Complejo Hospitalario  
Universitario A Coruña, 84 As Xubias, 15006 A Coruña, Spain  
e-mail: Luis.M.Anton.Aparicio@sergas.es

9. Motzer RJ, Escudier B, Tomczak P et al (2012) Axitinib vs sorafenib for advanced renal cell carcinoma: phase III overall survival results and analysis of prognostic factors. *Ann Oncol* 23(Suppl 9):IX262

**Table 2** Efficacy of targeted drugs as second-line treatment after progression to previous sunitinib

	Everolimus [6–8]	Axitinib [9, 10]	Sorafenib [9, 10]
PFS, months (95 % CI)	3.9	4.8 (4.5–6.4)	3.4 (2.8–4.7)
OS, months	–	15.2	16.5

Cross-trial comparison of PFS is biased by the fact that in the phase III trial testing everolimus versus placebo (RECORD-1), 53 % of patients progressing on previous targeted therapy had at least one previous therapy, often cytokines. In addition, PFS analysis in this trial was not specifically done for previous sunitinib treatment  
PFS progression-free survival, OS overall survival